Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
NGM Biopharmaceuticals
Biotech
BMS oncology head swings to Syndax—Chutes & Ladders
BMS oncology head swings to Syndax. Stylus unsheathes with Bayer vet at helm. T1D Fund picks up former BMS dealmaker.
Darren Incorvaia
,
Zoey Becker
May 16, 2025 8:30am
NGM Bio cuts 75% of staff, halts midstage liver disease program
May 12, 2025 7:00am
J&J vet jumps to Affinia—Chutes & Ladders
Feb 7, 2025 8:30am
VC firm pens $608M deal to direct NGM MASH drug to rare disease
Dec 19, 2024 10:30am
VC firm that took NGM private oversees biotech’s $122M series A
Jul 17, 2024 7:42am
NGM to go private as part of $135M buyout by VC firm Column
Feb 26, 2024 10:26am